Y/W whisky, i somewhat simplified my reply, in essence this was it,
of course with EMITF management at that time it was a more complex
In the meantime GOOG translate: The CFDA renewed and extended its approval for the treatment of VAT "of InSightec (36%) in China. Posted on 21/12/2014 08:51
InsighTec was established as a joint venture
equally owned by EMITF(via subsidiary)
hence all decisions are mutually agree
upon. It was not as if GE spun off Insightec.
"it has successfully completed its rights offering, which forms part of its restructuring plan "
ELBIT IMAGING LTD. ANNOUNCES CLOSING OF PLAZA'S RIGHTS OFFERING
Tel Aviv, Israel, December 19, 2014, Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today, following its announcements dated June 23, 2014, October 14, 2014 and November 28, 2014, that its subsidiary, Plaza Centers N.V. (LSE: PLAZ, WSE: PLZ/PLAZACNTR, TASE: PLAZ) (“Plaza”), announced that it has successfully completed its rights offering, which forms part of its restructuring plan ("Rights Offering").
Elbit Ultrasound (Luxembourg) B.V./S.a.r.l., a wholly owned subsidiary of the Company ("EUL") has purchased 122,847,376 new ordinary shares of Plaza under the Rights Offering and the arrangements under the Undertaking (as defined in the Company's previous announcement dated June 23, 2014) for an aggregate amount of approximately Euro 8.3 million and has procured that Burlington Loan Management Limited, an affiliate of Davidson Kempner Capital Management LP, a shareholder of the Company, will purchase 163,803,197 new ordinary shares of Plaza which represent 26.3% of Plaza for an additional amount of Euro 11.05 million.
Following the Rights Offering and associated placing of shares and the issuance of new ordinary shares to Plaza's bondholders under Plaza’s restructuring plan as announced by Plaza, EUL will hold 44.9% in the issued share capital of Plaza.
Plaza announced further that it is expected that (i) the new ordinary shares of Plaza (issued to the Plaza's shareholders and bondholders as described above) in uncertificated form will be credited to stock accounts on December 23, 2014; and (ii) such new ordinary shares of Plaza will commence trading, fully paid, on the London Stock Exchange plc's main market for listed securities and on the Warsaw Stock Exchange on December 23, 2014 and on the Tel Aviv Stock Exchange shortly thereafter.
Ha-ha, you own NO shares, and yet you got
your proxy from EMITF!
What a joker you are! Not that anybody gives
a hoot whether you own a single share or
not (beside your other self shadow twin)
INSIGHTEC will change the face of medicine and open a new therapeutic horizon that will benefit millions of patients," said Dr. Ferré.
INSIGHTEC Secures $59 Million in Equity Financing and Appoints Maurice R. Ferré, M.D., as Executive Chairman of the Board
TIRAT CARMEL, Israel, December 15, 2014 /PRNewswire/ --
INSIGHTEC announced today that it closed on a $59 Million Series D financing led by major institutional investors in the United States and Asia.
Dr. Maurice R. Ferré, a seasoned medical device executive, will join the INSIGHTEC leadership team as its newly appointed Executive Chairman of the Board of Directors. Dr. Ferré comes with over 20 years of experience in the medical device field. Dr. Ferré most recently served as CEO and Chairman of MAKO Surgical Corp, a transformational robotic surgical company that he co-founded in 2004, IPO'd in 2008 and recently sold to Stryker Corp. for $1.65 billion in late 2013.
"I am very excited to be part of the Company transforming the way surgery is being performed. INSIGHTEC is at the forefront of the global shift towards non-invasive surgery that has the potential to improve patient outcomes, reduce morbidity and trauma while also reducing cost. The $59 million round of financing assures that INSIGHTEC's impressive series of technological breakthroughs will continue. I am impressed that the Company just completed enrollment of an FDA pivotal study for the neurosurgical application of Essential Tremors. INSIGHTEC will change the face of medicine and open a new therapeutic horizon that will benefit millions of patients," said Dr. Ferré.
"We are pleased and honored to welcome Maurice to our board as our Executive Chairman," said Dr. Kobi Vortman, INSIGHTEC's CEO. "He has an impressive track record of building transformational companies. Maurice's commercial and clinical skills will help INSIGHTEC achieve widespread awareness and commercial adoption of our technology."
"We would also like to convey our appreciation to Tom Gentile, our former Chairman, who was recently appointed as President and Chief Operating Officer
Nothing of drama or substance is expected,
The agenda of the meeting is as follows:
1. To re-elect Elina Frenkel Ronen as one of the Company's external directors.